Gerald Chan
Direktor/Vorstandsmitglied bei Cognito Therapeutics, Inc.
Aktive Positionen von Gerald Chan
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Cognito Therapeutics, Inc.
 Cognito Therapeutics, Inc. BiotechnologyHealth Technology Cognito Therapeutics, Inc. is a clinical-stage neurotechnology company based in Cambridge, MA. Cognito Therapeutics is developing disease-modifying therapeutic approaches to treat neurodegenerative disorders using its non-invasive neuromodulation platform. The company's lead therapy is currently in a pivotal study (HOPE) in Alzheimer's disease and has been awarded FDA breakthrough device designation. Cognito Therapeutics is advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases. The company was founded by Li-Huei Tsai and Ed Boyden, and Brent A. Vaughan has been the CEO of the company since 2020. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Gerald Chan
Ehemalige bekannte Positionen von Gerald Chan
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Stavvy, Inc.
 Stavvy, Inc. Packaged SoftwareTechnology Services Stavvy, Inc. provides information technology services. The company is headquartered in Newton, MA. | Direktor/Vorstandsmitglied | - | - |
Statistik
International
| Vereinigte Staaten | 3 |
Operativ
| Director/Board Member | 2 |
Sektoral
| Technology Services | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Stavvy, Inc.
Stavvy, Inc. Packaged SoftwareTechnology Services Stavvy, Inc. provides information technology services. The company is headquartered in Newton, MA. | Technology Services |
Cognito Therapeutics, Inc.
Cognito Therapeutics, Inc. BiotechnologyHealth Technology Cognito Therapeutics, Inc. is a clinical-stage neurotechnology company based in Cambridge, MA. Cognito Therapeutics is developing disease-modifying therapeutic approaches to treat neurodegenerative disorders using its non-invasive neuromodulation platform. The company's lead therapy is currently in a pivotal study (HOPE) in Alzheimer's disease and has been awarded FDA breakthrough device designation. Cognito Therapeutics is advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases. The company was founded by Li-Huei Tsai and Ed Boyden, and Brent A. Vaughan has been the CEO of the company since 2020. | Health Technology |
- Börse
- Insiders
- Gerald Chan
- Erfahrung
